目的 探讨咖啡酸片联合艾曲泊帕乙醇胺片治疗血小板减少症的临床疗效。方法 选取2020年1月—2022年1月在郑州颐和医院治疗的63例血小板减少症患者为研究对象，根据用药的差别分为对照组（31例）和治疗组（32例）。对照组空腹口服艾曲泊帕乙醇胺片，50 mg/次，1次/d。在此基础上，治疗组患者口服咖啡酸片，0.3 g/次，3次/d。两组患者均治疗14 d。观察两组患者临床疗效，比较治疗前后两组患者急性生理学和慢性健康评估系统（APACHEII）评分和生活质量综合评定问卷（GQOLI-74）评分，血清血小板第4因子（PF4）、血小板生成素（TPO）、血管性血友病因子（vWF）和人类血小板抗原（HPA）水平，凝血功能指标血小板（PLT），凝血酶原时间（PT）和活化部分凝血活酶时间（APTT），血栓弹力图反应时间（R值）、凝固时间（K值）、凝固角（Angle角）和血栓最大幅度（MA值）。结果 治疗后，对照组有效率为80.65%，明显低于治疗组96.88%（P<0.05）。治疗后，两组APACHEII评分、GQOLI-74评分，血清PF4、TPO、vWF、HPA水平，凝血功能，以及R值、K值、Angle角和MA值均明显改善，并以治疗组改善的最为明显（P<0.05）。结论 咖啡酸片联合艾曲泊帕乙醇胺治疗血小板减少症能够有效改善患者凝血功能，促进患者生活质量改善。

Objective To investigate the clinical efficacy of Caffeic acid Tablets combined with Eltrombopag Olamine Tablets in treatment of thrombocytopenia. Methods Patients (63 cases) with thrombocytopenia in Zhengzhou Yihe Hospital from January 2020 to January 2022 were divided into control (31 cases) and treatment (32 cases) group based on different treatments. Patients in the control group were po administered with Eltrombopag Olamine Tablets before meals, 50 mg/time, once daily. Patients in the treatment group were po administered with Caffeic acid Tablets on the basis of the control group, 0.3 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, the scores of APACHEⅡ and GQOLI-74, the levels of serum cytokines PF4, TPO, vWF and HPA, the coagulation function indexes of PLT, PT and APTT, the thromboelastogram of R value, K, Angle and MA value in two groups before and after treatment were compared. Results After treatment, the effective rate of the control group was 80.65%, which was significantly lower than that of the treatment group 96.88% (P<0.05). After treatment, the scores of APACHE Ⅱ and GQOLI-74, serum PF4, TPO, vWF and HPA levels, coagulation function, R value, K value, Angle angle and MA value were significantly improved in two groups (P<0.05), especially in the treatment group (P<0.05). Conclusion Caffeic acid Tablets combined with Eltrombopag Olamine Tablets in treatment of thrombocytopenia can effectively improve the coagulation function and promote the quality of life of patients

R973

河南省医学科技攻关计划（联合共建项目）（2018020750）